Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). in Blood cells, molecules & diseases / Blood Cells Mol Dis. 2024 Sep;108:102860. doi: 10.1016/j.bcmd.2024.102860. Epub 2024 May 29.
2024
AOU Città della Salute di Torino
ASL Torino 4
Tipo pubblicazione
Practice Guideline
Autori/Collaboratori (40)Vedi tutti...
Zecca M
Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Fioredda F
Hematology Unit, IRCCS Giannina Gaslini Children Hospital, Genoa, Italy.
Verzegnassi F
Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
et alii...
Abstract
Acquired aplastic anemia (AA) is a rare heterogeneous disorder characterized by pancytopenia and hypoplastic bone marrow. The incidence is 2-3 per million population per year in the Western world, but 3 times higher in East Asia. Survival in severe aplastic anemia (SAA) has improved significantly due to advances in hematopoietic stem cell transplantation (HSCT), immunosuppressive therapy, biologic agents, and supportive care. In SAA, HSCT from a matched sibling donor (MSD) is the first-line treatment. If a MSD is not available, options include immunosuppressive therapy (IST), matched unrelated donor, or haploidentical HSCT. The purpose of this guideline is to provide health care professionals with clear guidance on the diagnosis and management of pediatric patients with AA. A preliminary evidence-based document prepared by a group of pediatric hematologists of the Bone Marrow Failure Study Group of the Italian Association of Pediatric Hemato-Oncology (AIEOP) was discussed, modified and approved during a series of consensus conferences that started online during COVID 19 and continued in the following years, according to procedures previously validated by the AIEOP Board of Directors.
Accesso banca dati bibliografica
Accedi alla scheda bibliografica del documento in PUBMED
PMID : 38889660
DOI : 10.1016/j.bcmd.2024.102860
Keywords
Guidelines; Anemia, aplastic; SARS-CoV-2; Immunosuppressive Agents/therapeutic use; Italy; COVID-19/diagnosis; Child; Hematopoietic Stem Cell Transplantation/adverse effects; Bone marrow failure; Humans; Anemia, Aplastic/therapy/diagnosis/etiology; Pediatric hematology/oncology;